Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,633.50 GBX | -0.31% | -1.09% | +12.64% |
07:28pm | Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says | MT |
06:41pm | GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push | DJ |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.64B | 5.75B | 4.38B | 14.96B | 4.93B | |||||
Depreciation & Amortization - CF | 1.23B | 1.21B | 1.2B | 1.06B | 1.08B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 870M | 896M | 957M | 1.09B | 1.01B | |||||
Depreciation & Amortization, Total | 2.1B | 2.11B | 2.15B | 2.15B | 2.09B | |||||
Amortization of Deferred Charges, Total - (CF) | 233M | 241M | 225M | - | 203M | |||||
(Gain) Loss From Sale Of Asset | -543M | -3.26B | -606M | -221M | -12M | |||||
(Gain) Loss on Sale of Investments - (CF) | -2M | -69M | 28M | -1M | -1M | |||||
Asset Writedown & Restructuring Costs | 825M | 781M | 523M | 198M | 360M | |||||
(Income) Loss On Equity Investments - (CF) | -74M | -33M | -33M | 2M | 5M | |||||
Stock-Based Compensation (CF) | 365M | 381M | 367M | 346M | 307M | |||||
Net Cash From Discontinued Operations | - | - | - | 769M | - | |||||
Other Operating Activities, Total | 99M | 2.58B | 714M | -9.44B | -257M | |||||
Change In Accounts Receivable | -32M | -224M | -782M | -158M | -794M | |||||
Change In Inventories | 300M | 119M | 25M | -269M | -424M | |||||
Change In Accounts Payable | 263M | 225M | 284M | 494M | -15M | |||||
Change in Other Net Operating Assets | -160M | -159M | 670M | -1.42B | 377M | |||||
Cash from Operations | 8.02B | 8.44B | 7.95B | 7.4B | 6.77B | |||||
Capital Expenditure | -1.26B | -1.23B | -1.17B | -1.14B | -1.31B | |||||
Sale of Property, Plant, and Equipment | 95M | 68M | 143M | 146M | 28M | |||||
Cash Acquisitions | -3.68B | -105M | -114M | -3.19B | -1.47B | |||||
Divestitures | 104M | 259M | -17M | -43M | 49M | |||||
Sale (Purchase) of Intangible assets | -494M | 242M | -987M | -919M | -1.02B | |||||
Investment in Marketable and Equity Securities, Total | -199M | 2.85B | 334M | 95M | 1.78B | |||||
Other Investing Activities, Total | 89M | 70M | 36M | -3.72B | 346M | |||||
Cash from Investing | -5.35B | 2.16B | -1.78B | -8.77B | -1.6B | |||||
Short Term Debt Issued, Total | 3.1B | - | 318M | 1.02B | - | |||||
Long-Term Debt Issued, Total | 4.79B | 3.3B | - | 1.02B | 223M | |||||
Total Debt Issued | 7.89B | 3.3B | 318M | 2.05B | 223M | |||||
Short Term Debt Repaid, Total | -4.16B | -7.3B | -2.31B | -5.07B | -2.45B | |||||
Long-Term Debt Repaid, Total | -214M | -227M | -215M | -1.8B | -341M | |||||
Total Debt Repaid | -4.37B | -7.53B | -2.53B | -6.87B | -2.79B | |||||
Issuance of Common Stock | 51M | 29M | 21M | 25M | 10M | |||||
Repurchase of Common Stock | - | - | - | - | - | |||||
Common Dividends Paid | -3.95B | -3.98B | -4B | -3.47B | -2.25B | |||||
Common & Preferred Stock Dividends Paid | -3.95B | -3.98B | -4B | -3.47B | -2.25B | |||||
Special Dividend Paid | - | - | - | - | - | |||||
Other Financing Activities, Total | -1.45B | -1.95B | -1.4B | 9.09B | -837M | |||||
Cash from Financing | -1.84B | -10.13B | -7.59B | 823M | -5.64B | |||||
Foreign Exchange Rate Adjustments | -82M | -39M | -29M | 152M | -99M | |||||
Net Change in Cash | 744M | 431M | -1.44B | -394M | -567M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 895M | 864M | 786M | 848M | 766M | |||||
Cash Income Tax Paid (Refund) | 1.51B | 1.66B | 1.29B | 1.31B | 1.33B | |||||
Levered Free Cash Flow | 5.01B | 8.05B | 6.47B | 4.95B | 3.56B | |||||
Unlevered Free Cash Flow | 5.56B | 8.59B | 6.95B | 5.46B | 4.01B | |||||
Change In Net Working Capital | 801M | -1.52B | -1.35B | -454M | 1.52B | |||||
Net Debt Issued / Repaid | 3.52B | -4.23B | -2.21B | -4.82B | -2.57B |